Albumedix improves patient outcome with a range of albumin-based products and technologies that facilitate the development of superior biotherapeutics.
Albumedix develops albumin-based products and technologies for advanced drug and vaccine formulation, extended drug half-life and improved drug delivery. Our products and technologies are used in clinical and marketed drugs and out-licensed to pharmaceutical and biotech companies worldwide. With over 25 years’ experience in the biopharmaceutical industry, we have the scientific, technical and regulatory expertise needed to support companies in moving faster to market with superior biotherapeutics. We also use this expertise to strengthen our own drug pipeline. Albumedix is a global company and a fully owned subsidiary of Novozymes A/S
Our brand promise
The Albumedix brand encapsulates the values by which we work, as well as the past and future of our company. Our logo depicts the heart-shaped albumin molecule in a soft-edged hexagon ring, recognizable as a benzene ring arrangement, it balances both our ambition and promise of creating superior biotherapeutics for improved patient outcomes.
The heart-shape represents the symbolic way albumin is illustrated today, while also reminding us of the many important ways by which it helps improve lives.
By wrapping the albumin molecule gently into a hexagonal ring, we wanted to capture and symbolize the innovative and scientific mentality by which we approach the albumin molecule.
Finally, the encapsulated albumin heart rests above our company name, Albumedix which answers both why we exist and what we offer in one word, namely to improve patient outcomes with a range of albumin-based products and technologies that facilitate the development of superior biotherapeutics.